Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 66 |
| Active Pipeline (Recruiting Now) | 30 (13) |
| Completed vs Stopped Early | 32 / 0 (0.0%) |
| Median Closed Actual Enrollment | 171 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University First Hospital | Beijing, Beijing Municipality | 6 |
| West China Hospital of Sichuan University | Chengdu, Sichuan | 4 |
| Xiangya Hospital of Central South University | Changsha, Hunan | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07390123 | Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN | Phase III | RECRUITING |
| NCT07442877 | A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Phase II | COMPLETED |
| NCT05890053 | To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Haisco Pharmaceutical Group Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.